FULC Fulcrum Therapeutics, Inc.
Mergers ·
Fulcrum's holders would own 5.0% of the combined company, after an estimated $270.0 million cash dividend paid before closing. The release reports no efficacy data for Slate's lead drug, whose first readout in mid-2027 covers safety and pharmacokinetics in healthy volunteers.
The restructuring follows the discontinuation of pociredir for sickle cell disease and carries expected charges of approximately $4.2 million. Leerink Partners LLC is advising the board.
Fulcrum ends pociredir, its lead sickle cell program, after FDA concerns about malignancy risk, and sets no timeline for its strategic review. It reported $333.3 million in cash, cash equivalents and marketable securities as of March 31, 2026.
The $150.0 million offering priced on December 10, 2025 at $13.50 a share and was upsized to $175.0 million. Its lead drug data come from 12 patients in one dose cohort, and the dose comparison rests on six.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $56.1 million | $63.4 million |
| Net income (loss) | -$74.9 million | -$9.7 million |
| Cash from operations | -$60.1 million | -$2.2 million |
| Cash and equivalents | $197.5 million | $58.2 million |
Our latest story on this, dated Dec 8, 2025: "Fulcrum proposes $150.0 million stock offering, later upsized to $175.0 million". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 17, 2026: "Fulcrum Therapeutics agrees to all-stock merger with Slate Medicines". The story links the filing or release it is based on. Read the story.
Fulcrum Therapeutics, Inc. trades under the ticker FULC on NASDAQ.
Fulcrum Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Fulcrum Therapeutics, Inc. is 1680581. Its filings are on SEC EDGAR.
76,297,257 shares as of 2026-07-23, per the cover page of its 10-Q filed 2026-07-30.
Our directory records Fulcrum Therapeutics, Inc. under United States.
Our directory classifies Fulcrum Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Fulcrum Therapeutics, Inc. is US3596161097.
aibio.space lists Fulcrum Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Fulcrum Therapeutics, Inc. reported a net loss of $74.9 million for the fiscal year ended Dec 31, 2025, and used $60.1 million of cash in operations, per its annual report to the SEC.
$56.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
$48.5 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Fulcrum Therapeutics, dated Aug 17, 2026: "Fulcrum Therapeutics agrees to all-stock merger with Slate Medicines". Fulcrum's holders would own 5.0% of the combined company, after an estimated $270.0 million cash dividend paid before closing. The release reports no efficacy data for Slate's lead drug, whose first readout in mid-2027 covers safety and pharmacokinetics in healthy volunteers. Source.
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,5.01,5.02,7.01,9.01). Source
Reported a leadership departure tied to a disagreement or a restructuring. SEC Form 8-K (Items 5.02). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 8.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,2.02,5.02,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,8.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio